TGN1412: From Discovery to Disaster
Attarwala H1★★ Corresponding author
- 1Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, USA.
CORRESPONDENCE
Attarwala H
Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, USA.
Volume 2, Issue 3 · pp. 332–336 · PUBLISHED · DOI: 10.4103/0975-1483.66810
ABSTRACT
After a drug is confirmed as safe and efficacious in preclinical studies, it is tested in healthy human volunteers for first in man trials. In 2006, a phase I clinical study was conducted for a CD28 superagonist antibody TGN1412 in six human volunteers. After very first infusion of a dose 500 times smaller than that found safe in animal studies, all six human volunteers faced life-threatening conditions involving multiorgan failure for which they were moved to intensive care unit. After this particular incident, a lot was changed over how first in man trials are approved by regulatory authorities and the way clinical trials are conducted. This review primarily deals with preclinical studies conducted by TeGenero, results of which encouraged them to test the antibody on human subjects, reasons why this drug failed in human trial and aftermath of this drug trial. In addition, another drug—Fialuridine which failed in phase 2 clinical trial leading to death of five human subjects is briefly reviewed.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
H, A. (). TGN1412: From Discovery to Disaster. Journal of Young Pharmacists, 2(3), 332–336. https://doi.org/10.4103/0975-1483.66810